An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Inqovi

Chemical Namedecitabine and cedazuridine
Dosage FormTablets; (oral; 35 mg decitabine and 100 mg cedazuridine)
Drug ClassMiscellaneous
SystemBlood
CompanyOtsuka Pharmaceutical Co.
Approval Year2020

Indication

  • For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS.
Last updated on 12/7/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Inqovi (decitabine and cedazuridine) Prescribing Information.2020Otsuka Pharmaceutical Co., Japan
Document TitleYearSource
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.2020Blood